Kaleido Biosciences Inc (KLDO) USD0.001
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The Company is also advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with unmet patient needs. The Company utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. Its KB195 is the lead MMT candidate for development in the treatment of patients with urea cycle disorders. The Company is conducting a Phase II clinical trial under an Investigational New Drug Application (IND).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.